IDO1 is considered a negative prognostic factor in tumors because of its ability to induce an immune-suppressed environment despite the failure of a recent clinical trial using an IDO1-selective enzyme inhibitor in combination with an anti-PD1 antibody in advanced melanoma (Muller et al, 2019). This evidence concerns the gene IDO1 and melanoma.